Healthcare costs of mCRPC in university hospitals in Japan
The study was a local, retrospective, observational, single-cohort study based on secondary data and was conducted to determine the healthcare costs in metastatic castration resistant prostate cancer (mCRPC) in national university hospitals in Japan.
- Patients who have been coded as having “Malignant neoplasm of prostate" (ICD-10, C61) at least once - Of the above patients those with at least one confirmed bone metastases site coded as “Secondary malignant neoplasm of other and unspecified sites" (ICD-10, C79) - Of the above patients those who have been coded as having “Bone metastatic prostate cancer" (ICD-10, C795) and received Androgen Deprivation Therapy (ADT) at least once since diagnosis or CRPC treatment (Abiraterone acetate, Enzalutamide, Docetaxel, Cabazitaxel) at least once since diagnosis. - Patients who have been coded as having “Castration-resistant prostate cancer” (ICD-10, C61 and Japanese 8848040)
- Patients who have been observed less than 6 months
Healthcare costs of metastases castration resistant prostate cancer (mCRPC) in national university hospitals in Japan